A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study

Ki vehet részt

• Male or female patients with documented diagnosis of DEB or JEB, confirmed by genetic testing and/or by a skin biopsy with immunofluorescence mapping
• Patients ≥4 years old. Note: Initially, patients ≥12 years will be enrolled. Enrollment will be open to 4 to 11 year old pediatric patients (both inclusive), after a DMC reviews and provides a positive opinion regarding the safety and tolerability of the IMP in at least 3 patients 12 to 18 years old who have completed at least 4 weeks of IMP use

Ki nem vehet részt

• The patient is currently being treated or planned to be treated with systemic antibiotics; Note: Use of preventive and/or anti-inflammatory antibiotic treatment, including doxycycline, on an established treatment regimen (stable dose for ≥6 weeks before the Baseline Visit) is permitted. Use of topical antibiotics on the index wounds within 7 days before the Baseline Visit is prohibited
• Use of systemic corticosteroids \>0.2 mg/kg prednisone dose equivalent per day within 30 days or use of topical corticosteroids on index wounds within 7 days before the Screening Visit; Note: Corticosteroids for inhalation, ophthalmic, or intranasal use are permitted
• The patient has a history of or current malignancy over the index wound, eg, basal cell carcinoma or squamous cell carcinoma
• The patient has any subtype of EB other than DEB or JEB